Research Highlight |
Featured
-
-
News & Views |
Long COVID and cardiovascular disease: a learning health system approach
Cardiovascular disease is both a risk factor and potential outcome of the direct, indirect and long-term effects of COVID-19. A recent analysis in >150,000 survivors of COVID-19 demonstrates an increased 1-year risk of numerous cardiovascular diseases. Preventing and managing this new disease burden presents challenges to health systems and requires a learning health system approach.
- Mohamed O. Mohamed
- & Amitava Banerjee
-
Research Highlight |
RAAS inhibitors do not increase the risk of COVID-19
According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.
- Irene Fernández-Ruiz
-
Correspondence |
Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
- Ying-Ying Zheng
- , Yi-Tong Ma
- & Xiang Xie
-
Correspondence |
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
- Jean-Jacques Mourad
- & Bernard I. Levy
-
Comment |
COVID-19 and the cardiovascular system
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system. Therefore, particular attention should be given to cardiovascular protection during treatment for COVID-19.
- Ying-Ying Zheng
- , Yi-Tong Ma
- & Xiang Xie
-
Review Article |
Infective endocarditis: innovations in the management of an old disease
Infective endocarditis (IE) is not a common disease, but it has a poor prognosis. In this Review, contemporary findings concerning the epidemiology, diagnosis, therapeutic management and prevention of IE are highlighted, with a particular emphasis on innovations and changes in guidelines.
- Bernard Iung
- & Xavier Duval
-
Research Highlight |
Pushing the envelope to prevent CIED infection
Use of an absorbable antibacterial envelope is a safe and effective strategy for reducing major infections related to cardiac implantable electronic devices.
- Isobel Leake
-
-
Review Article |
Cardiovascular manifestations of the emerging dengue pandemic
Dengue is one of the most important emerging infectious viral diseases in the world. Cardiovascular complications of dengue, including myocardial impairment and arrhythmias, are increasingly recognized. Capillary leakage is frequently described, with a small proportion of patients developing hypovolaemic shock. In this Review, Yacoub et al. outline our current understanding of the pathophysiology of the cardiovascular manifestations of dengue, and discuss the available management options for this disease.
- Sophie Yacoub
- , Heiman Wertheim
- & Bridget Wills
-
Review Article |
Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity
The number of patients undergoing implantation of a cardioverter-defibrillator (ICD) is increasing, as the indications for device therapy have broadened. Despite the mortality benefits associated with ICDs, they can also cause substantial complications. Drs. Wazni and Wilkoff explore the issues involved in managing patients with an ICD and discuss approaches for reducing these adverse effects, from prevention of infection, and the choice of lead and implantation technique, to strategies for programming and monitoring the device.
- Oussama Wazni
- & Bruce L. Wilkoff
Endocarditis: oral versus intravenous antibiotics